Cushman & Wakefield Advises On Sale Of Development Site For Commercial Campus At The London Cancer Hub
23/01/2024
Following competitive bidding rounds, Aviva Capital Partners, and mixed-use developer, Socius, were selected as the preferred party to deliver the laboratory-led scheme last October. The partners have now successfully exchanged on the acquisition of the 12-acre development site, with a 1-million-square-foot (sq ft) development capacity.
Aviva and Socius will now progress the development of a major new commercial life sciences project, which, together with campus partners the Institute of Cancer Research (ICR), the Royal Marsden NHS Foundation Trust and Epsom & St Helier University Hospitals NHS Trust, will form Europe’s leading oncology-focussed R&D and treatment cluster.
The London Cancer Hub, which could contribute circa £1.2bn to the UK economy, is a multi-phased mixed-use scheme which will include the development of best-in-class laboratories and commercial buildings, as well as accommodation to support keyworkers, amenities and green spaces open to the public.
Once completed, the globally recognised district for cancer research will provide more than 13,000 jobs and create a vibrant community of scientists, clinicians, biotech, and pharmaceutical companies working in collaboration in pursuit of new cancer treatments for patients, as well as driving economic growth.
Michael Aston, Head of UK Life Sciences at Cushman & Wakefield, said: “It was a real privilege to support the London Borough of Sutton in securing a funder and developer for the delivery of the commercial campus at the London Cancer Hub. Part of our role as advisors during the two-year process was to design a commercial structure that would be attractive to investors, while providing assurance to the council of the delivery of their vision. Among other things, it was crucial to secure long-term investors with experience in delivering complex life sciences developments and a strong commitment to placemaking. Once completed, this 12-acre development will complete the London Cancer Hub’s bench-to-bedside ecosystem, where world-class academic research can be translated into therapies by biotech companies for the benefit of patients locally and far beyond. The project will also bring substantial local benefits in terms of quality of place, access, and amenities.”
Cushman & Wakefield (NYSE: CWK) is a leading global commercial real estate services firm for property owners and occupiers with approximately 52,000 employees in nearly 400 offices and 60 countries. In 2023, the firm reported revenue of $9.5 billion across its core services of property, facilities and project management, leasing, capital markets, and valuation and other services. It also receives numerous industry and business accolades for its award-winning culture and commitment to Diversity, Equity and Inclusion (DEI), sustainability and more. For additional information, visit www.cushmanwakefield.com.
What's new
Cushman & Wakefield Advises On The Sale of The Holiday Inn Express Southampton
Cushman & Wakefield’s UK Hospitality team has advised Brightbay Real Estate Partners (BBREP) on the sale of the Holiday Inn Express Southampton, M27 J7 to UK-based family office Hunton Hotels.
21/12/2023
Cushman & Wakefield Welcomes Senior Hire To UK Capital Markets Team
Global real estate services firm, Cushman & Wakefield, has appointed James Yates as a Partner to its UK Capital Markets team.
24/11/2023
MyCity 2023
This autumn, we’re excited to unpack our vision for the future of six UK cities: London, Birmingham, Bristol, Manchester, Leeds and Edinburgh. We consider how well placed each is to manage the challenges and opportunities ahead.
Insights
Research
Research
Build To Rent Quarterly Report
Research
Elderly Care Real Estate Scorecard
MarketBeat
Hospitality Market Trends & Data
The latest hospitality market insights are based on the in-depth analysis of our extensive data sets, surveys of investors, operators and lenders and up-to-date market intelligence from our team members on-the-ground in all major European markets.